麗珠醫藥(01513.HK)預計上半年純利增長30%-40%
格隆匯7月14日丨麗珠醫藥(01513.HK)發佈公告,2020年1月1日至2020年6月30日,公司預計歸屬於上市公司股東的淨利潤約人民幣9.6億元-10.3億元,比上年同期增長約30.00%-40.00%;歸屬於上市公司股東的扣除非經常性損益的淨利潤約人民幣7.9億元-8.56億元,比上年同期增長約20.00%-30.00%。
公司2020年半年度經營業績與上年同期相比同向上升的主要原因是:1、出售江蘇尼科醫療器械有限公司股權增加了公司歸屬於母公司的淨利潤約為人民幣8523.99萬元;2、2020年上半年,受新型冠狀病毒肺炎疫情影響,公司處方藥相關產品銷售雖未達預期,但由於抗病毒顆粒及注射用艾普拉唑鈉同比去年上半年大幅增長,加之新型冠狀病毒抗體檢測試劑產品實現新增銷售,為公司整體業績增長提供了重要支持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.